fluoxetine and duloxetine

fluoxetine has been researched along with duloxetine in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (50.00)	29.6817
2010's	7 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beedle, EE; Bymaster, FP; Findlay, J; Gallagher, PT; Krushinski, JH; Mitchell, S; Robertson, DW; Thompson, DC; Wallace, L; Wong, DT	1
Morphy, R; Rankovic, Z	1
Bish, G; Brown, AD; Fish, PV; Jonathan Fray, M; Stobie, A; Wakenhut, F; Whitlock, GA	1
Bish, G; Fish, PV; Fray, MJ; Stobie, A; Wakenhut, F; Whitlock, GA	1
Alfinito, P; Bray, J; Cohn, ST; Deecher, DC; Fensome, A; Johnston, G; Koury, E; Mahaney, PE; Marella, MA; McComas, CC; Nogle, L; Trybulski, EJ; Vu, AT; Ye, F; Zhang, P	1
Childers, SR; Davies, HM; Manning, JR; Sexton, T	1
Bray, JA; Cohn, ST; Deecher, DC; Dooley, R; Goljer, I; Johnston, GH; Leiter, J; Mahaney, PE; Moore, WJ; Terefenko, EA; Trybulski, EJ; Vu, AT; Zhang, P	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Bray, JA; Cohn, ST; Cosmi, SA; Deecher, DC; Harrison, JE; Johnston, GH; Kennedy, JD; Kim, CY; Koury, EJ; Leventhal, L; Mahaney, PE; Smith, VA; Trybulski, EJ; Vu, AT; Whiteside, GT; Zhang, P	1
Burroughs, K; Cosmi, S; Deecher, DC; Ho, D; Johnston, G; Leiter, J; Mahaney, PE; Sabatucci, JP; Trybulski, E; Zhang, Y	1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC	1
Cheon, SH; Choi, K; Hahn, HG; Han, M; Song, C; Yun, J	1
Hahn, HG; Han, M; Jeong, N; Song, C	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1

Reviews

2 review(s) available for fluoxetine and duloxetine

Article	Year
Designed multiple ligands. An emerging drug discovery paradigm. Journal of medicinal chemistry, 2005, Oct-20, Volume: 48, Issue:21 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors	2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Article

Year

Designed multiple ligands. An emerging drug discovery paradigm.

Journal of medicinal chemistry, 2005, Oct-20, Volume: 48, Issue:21

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors

2005

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.

Drug discovery today, 2016, Volume: 21, Issue:4

Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

12 other study(ies) available for fluoxetine and duloxetine

Article	Year
Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorganic & medicinal chemistry letters, 2003, Dec-15, Volume: 13, Issue:24 Topics: Antidepressive Agents; Binding Sites; Clinical Trials as Topic; Depressive Disorder; Duloxetine Hydrochloride; Humans; Kinetics; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Thiophenes	2003
N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorganic & medicinal chemistry letters, 2006, Aug-15, Volume: 16, Issue:16 Topics: Amines; Chemistry, Pharmaceutical; Drug Design; Duloxetine Hydrochloride; Humans; Models, Chemical; Norepinephrine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Thiophenes	2006
Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorganic & medicinal chemistry letters, 2006, Aug-15, Volume: 16, Issue:16 Topics: Amines; Biological Transport; Cell Line; Chemistry, Pharmaceutical; Drug Design; Humans; Inhibitory Concentration 50; Models, Chemical; Piperazine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship	2006
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. Bioorganic & medicinal chemistry letters, 2008, Sep-15, Volume: 18, Issue:18 Topics: Humans; Indoles; Molecular Structure; Neurotransmitter Uptake Inhibitors; Norepinephrine; Stereoisomerism; Structure-Activity Relationship	2008
1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. Bioorganic & medicinal chemistry letters, 2009, Jan-01, Volume: 19, Issue:1 Topics: Amines; Animals; Antidepressive Agents, Second-Generation; Biogenic Monoamines; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Design; Humans; Neurotransmitter Uptake Inhibitors; Protein Binding; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stereoisomerism	2009
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors. Bioorganic & medicinal chemistry letters, 2009, May-01, Volume: 19, Issue:9 Topics: Adrenergic Uptake Inhibitors; Animals; Chemistry, Pharmaceutical; Dogs; Dopamine Plasma Membrane Transport Proteins; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Norepinephrine; Propanolamines; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors. Journal of medicinal chemistry, 2010, Mar-11, Volume: 53, Issue:5 Topics: Animals; Body Temperature Regulation; Female; Indoles; Magnetic Resonance Spectroscopy; Neurotransmitter Uptake Inhibitors; Norepinephrine Plasma Membrane Transport Proteins; Pain; Propanolamines; Rats; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship	2010
Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors. Bioorganic & medicinal chemistry letters, 2010, May-01, Volume: 20, Issue:9 Topics: Animals; Crystallography, X-Ray; Ethylamines; Humans; Molecular Conformation; Neurotransmitter Uptake Inhibitors; Norepinephrine; Piperazines; Rats; Structure-Activity Relationship; Thiophenes	2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24 Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility	2010
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors. Bioorganic & medicinal chemistry letters, 2014, Aug-01, Volume: 24, Issue:15 Topics: Azetidines; Biological Transport; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Phenyl Ethers; Plasma Membrane Neurotransmitter Transport Proteins; Serotonin; Structure-Activity Relationship	2014
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine. ACS medicinal chemistry letters, 2014, Sep-11, Volume: 5, Issue:9 Topics:	2014